Evidence map›Paper›PMID 39306812›Full record

ArticleCancer causes & control : CCC2025

Investigating the coverage of the Arkansas All-Payer Claims Database for examining health disparities related to persistent poverty areas in colorectal cancer patients.

Chenghui Li, Cheng Peng, Peter DelNero, Jonathan Laryea, Daniela Ramirez Aguilar, Güneş Koru, Yong-Moon Mark Park, Mahima Saini, Mario Schootman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer causes & control : CCC, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chenghui LiDivision of Pharmaceutical Evaluation and Policy, Department of Pharmacy Practice, University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR, USA.
Cheng PengDivision of Pharmaceutical Evaluation and Policy, Department of Pharmacy Practice, University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR, USA.
Peter DelNeroDepartment of Internal Medicine, University of Arkansas for Medical Sciences College of Medicine, Little Rock, AR, USA.
Jonathan LaryeaDepartment of Surgery, and Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Daniela Ramirez AguilarArkansas Department of Health, Arkansas Central Cancer Registry, Little Rock, AR, USA.
Güneş KoruDepartment of Health Policy and Management and Department of Biomedical Informatics, University of Arkansas for Medical Sciences College of Public Health , Little Rock, AR, USA.
Yong-Moon Mark ParkDepartment of Epidemiology, Fay W. Boozman College of Public Health, and Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Mahima SainiDivision of Pharmaceutical Evaluation and Policy, Department of Pharmacy Practice, University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR, USA.
Mario SchootmanDepartment of Internal Medicine, University of Arkansas for Medical Sciences College of Medicine, Little Rock, AR, USA. MSchootman@uams.edu.

Funding

Expanding Translational Research in ArkansasUL1TR003107 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI JAMES, LAURA P · 2019 to 2023
$21.6M
American Cancer Society RSGI-23-1039245-01-HOPSNCATS NIH HHS UL1 TR003107NCATS NIH HHS UL1 TR003107-02S2
6 · The paper itself

Abstract

purposeWe aimed to (1) determine the extent of coverage of colorectal cancer patients in Arkansas All-Payer Claims Database (APCD), (2) assess coverage difference between persistent poverty and other areas, and (3) identify patient, tumor, and area factors associated with inclusion in APCD.

methodsData were from 2018 to 2020 Arkansas APCD linked with 2019 Arkansas Central Cancer Registry (ACCR). We constructed four cohorts to assess APCD's coverage of CRC patients: (Cohort 1) ≥ 1 day of medical coverage in APCD in 2019; (Cohort 2) APCD coverage in the diagnosis month; continuous APCD coverage in the 30; Year around diagnosis (six months before to five months after diagnosis month) (Cohort 3); or until death within six months (Cohort 4). We compared proportions in the cohorts by area persistent poverty designation. Logistic regressions identified factors associated with inclusion in APCD cohorts. PATIENT SELECTION: CRC patients diagnosed in 2019 from ACCR, excluding in situ disease.

resultsOf the 1,510 CRC patients diagnosed in 2019, 83% had ≥ 1 day of medical coverage in 2019 APCD (Cohort1), 81% had coverage in the diagnosis month (Cohort 2), and 63% had continuous coverage in the year around diagnosis (Cohort 3). Additionally, 11% died within six months but had continuous coverage until death (Cohort 4, 74%). No coverage difference was found between persist poverty and other areas. Age and primary payer type at diagnosis were the main predictors of inclusion in APCD.

conclusionArkansas APCD had high coverage of Arkansas CRC patients. No selection bias by area of persistent poverty designation was present.

Indexed as

Colorectal NeoplasmsHealthcare DisparitiesInsurance CoveragePoverty AreasAdultAgedArkansasDatabases, FactualFemaleHumansMaleMiddle AgedPovertyRegistriesAll-payer claims databaseColorectal cancerDisparityPersistent poverty areas

Identifiers

PMID39306812
PMCPMC13064871

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.